61/108US=84-A / Biol/Mol
Yasui H, Hideshima T, Anderson KC. Transformig growth factor-B in developing and advanced cancers: inhibition of TGF-B signaling in multiple myeloma and its bone marrow microenvironment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 219-27. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IL-6; VEGF; TGF-B RECEPTOR TIPO I; TBRI; MIELOMA MULTIPLO; MICROAMBIENTE DA MEDULA OSSEA; FATOR TRANSFORMADOR DE CRESCIMENTO; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DE QUINASE SD-208

62/108US=84-A / Biol/Mol
Reiss M. Development of inhibitors of transforming growth factor-B signaling for therapy: targetin transforming growth factor-B in metastasis: in vitro and in vivo mechanisms. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 609-34. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FATOR TRANSFORMADOR DE CRESCIMENTO - B; ANGIOGENESE; CANCER; MOTILIDADE; RESPOSTA IMUNE; INVASAO; METASTASE; TGF-B DO TIPO I; INIBIDOR DA QUINASE DO RECEPTOR; CRESCIMENTO TUMORAL

63/108US=90 / Biol/Mol
Domin J. EGFR signaling networks: phosphoinositide 3-kanase enzymes as downstrem targets of the EGF receptor. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 97-117. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

AKT; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR; QUINASE; FOSFATIDILINOSITOL; TRANSDUCAO DE SINAL; CELULA; CANCER; MITOGENESE; APOPTOSE; ENDOCITOSE

64/108US=90 / Biol/Mol
Bennett HL, Brummer T, Timpson P, Patterson KI, Daly RJ. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: signaling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 235-55. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

SRC; RAS; RAF; ERK; PI3-QUINASE; PTEN; EGFR INIBIDORES; LOOPS DE FEEDBACK; C-CBL; ENDOCITOSE

65/108US=90 / Biol/Mol
Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO

66/108US=90 / Biol/Mol
Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA

67/108US=1 / Química
Harnett MM, Goodridge HS. Receptores de membrana e transdução de sinal. In: Baynes JW, Dominiczak MH. Bioquímica médica. 2ª ed. Rio de Janeiro: Elsevier, 2007. p. 557-74. ISBN 85-3522298-2.

RECEPTORES HORMONAIS; HORMONIOS ESTEROIDES; HORMONIOS PEPTIDIOS; TRANSDUCAO DO SINAL INTRACELULAR; PROTEINA G; AMP CICLICO; PROTEINA QUINASE A; FOSFODIESTERASES; ION CALCIO; CALMODULINA; FOSFATIDILINOSITOL 4,5-BIFOSFATO; 1,4,5-TRIFOSFATO DE INOSITOL; DIACILGLICEROL; FOSFOLIPASE; ACIDO ARAQUIDONICO; EICOSANOIDES; LEUCOTRIENO

68/108US=111 / Câncer
Carraway KL, Carraway CAC. Signalling by tyrosine kinases. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 212-25. ISBN 978-0-470-01852-1.

CANCER; SINALIZACAO POR TIROSINA-QUINASES; RECEPTOR TIROSINA-QUINASE

69/108US=111-A / Câncer
Molife R, Collins I, Workman P, Kaye SB. Rational drug design of small molecule anticancer agents: early clinical development. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 1216-41. ISBN 978-0-470-01852-1.

CANCER. TERAPIA; MEDICAMENTOS; AGENTES DE PEQUENAS MOLECULAS ANTICANCER; DESENVOLVIMENTO CLINICO PRECOCE; INIBIDORES HSP 90; CICLINA DEPENDENTE DE INIBIDORES DE QUINASE; HISTONA DEACETILASES; FOSFOINOSITIDEO 3-QUINASE; FOSFATIDILINOSITOL 3-QUINASES

70/108US=21 / Neurologia
Vogelbaum M, Thomas T. Contemporary investigational treatments: small molecule agents. In: Barnett GH. High-grade gliomas: diagnosis and treatment. New Jersey: Humana Press, 2007. p. 337-56. (Current Clinical Oncology) ISBN 978-1-58829-511-8.

GLIOMA DE ALTO GRAU. TERAPIA; AGENTES MOLECULARES; INIBIDORES DE GLIOMA; FATORES DE CRESCIMENTO; DROGAS DE MOLECULAS PEQUENAS; TERAPIA-ALVO; INIBIDORES DE QUINASE DE TIROSINA

71/108US=35 / Câncer
Levis M. Molecular therapeutics of AML: FLT3: a prototype receptor tyrosine kinase target in AML. In: Karp JE. Acute myelogenous leukemia. New Jersey: Humana Press, 2007. p. 247-61. (Contemporary Hematology) ISBN 978-1-58829-621-4.

LEUCEMIA MIELOIDE AGUDA; QUINASE; FLT3; PROGNOSTICO; INIBIDORES; CELULAS TRONCO

72/108US=68 / Biol/Mol
Dent P, Hylemon PB, Grant S, Fisher PB. Approaches for monitoring signal transduction changes in normal and cancer cells. In: Fisher PB. Cancer genomics and proteomics: methods and protocols. New Jersey: Humana Press, 2007. p. 259-76. (Methods in Molecular Biology, 383) ISBN 978-1-58829-504-0.

TRANSDUCAO DE SINAL; MONITORAMENTO EM CELULAS NORMAIS; MONITORAMENTO EM CELULAS CANCEROSAS; QUINASE; FOSFORILACAO; FOSFORO ESPECIFICO; IMUNOPRECIPITACAO; ERK1/2; MAP QUINASE; JNK1/2; P38; AKT; RAF-1; B-RAF; CDK

73/108US=92 / Biol/Mol
Dent P, Curiel DT, Fisher PB. Resistance and sensitization: resistance/signaling pathways. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 281-98. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

RADIACAO; SINALIZACAO; QUINASE; FOSFATASE; ESPECIES REATIVAS DE OXIGENIO / NITROGENIO; RECEPTOR

74/108US=92 / Biol/Mol
Smith DL, Nolden LK, Mills GB, Lu Y. Resistance and sensitization: chemo-and radiosensitization through inhibition of PI3K/Akt signaling. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 313-34. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

FOSFATIDILINOSITOL 3-QUINASE; AKT; SIGNALTRANSDUCTION; TERAPIA ALVO MOLECULAR; QUIMIOSSENSIBILIZACAO; RADIOSSENSIBILIZACAO

75/108US=92 / Biol/Mol
Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA

76/108US=2 / Biol/Mol
Mehlen P, Lourenço FC. Death receptor: dependence receptors and apoptosis. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 157-82. ISBN 978-3-527-31237-5.

RECEPTOR DE MORTE; RECEPTORES DE DEPENDENCIA; APOPTOSE; INTEGRINA; TIROSINA QUINASE

77/108US=2 / Biol/Mol
Scheid MP, Woodgett JR. Survival pathways: cell survival through phosphoinositide 3-kinase and protein kinase B. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 463-89. ISBN 978-3-527-31237-5.

SOBREVIVENCIA CELULAR; FOSFATIDILINOSITOL 3-QUINASE; PROTEINA QUINASE B; MTOR

78/108US=2-A / Biol/Mol
Graville CA, Memmott RM, Gills JJ, Dennis PA. Molecular targets and therapeutics: targeting the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin pathway. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 966-96. ISBN 978-3-527-31237-5.

ALVOS MOLECULARES; TERAPEUTICA MOLECULAR; RAPAMICINA; FOSFOINOSITIDE-3-QUINASE; AKT; P13K/AKT

79/108US=55 / Biol/Mol
Staub M, Eriksson S. The role of deoxycytidine kinase in DNA synthesis and nucleoside analog activation. In: Peters GJ. Deoxynucleoside analogs in cancer therapy. New Jersey: Humana Press, 2006. p. 29-52. (Cancer Drug Discovery and Development) ISBN 978-1-58829-327-5.

DESOXICITIDINA-QUINASE; SINTESE DE DNA; ATIVACAO ANALOGO DE NUCLEOSIDEO; DESOXICITIDINA QUINASE; QUINASE DEOXIGUANOSINE; ANALOGOS DESOXINUCLEOSIDOS; DESOXINUCLEOSIDO QUINASE; TIMIDINA QUINASE

80/108US=55 / Biol/Mol
Munch-Petersen B, Piskur J. Deoxynucleoside kinases and their potential role in deoxynucleoside cytotoxicity. In: Peters GJ. Deoxynucleoside analogs in cancer therapy. New Jersey: Humana Press, 2006. p. 53-79. (Cancer Drug Discovery and Development) ISBN 978-1-58829-327-5.

QUINASES DESOXINUCLEOSIDOS; CITOTOXICIDADE; DEOXIRIBONUCLEOSIDEOS; QUINASE; ANALOGOS NUCLEOSIDEOS; QUIMIOTERAPIA

Primeira | Anterior | Próxima | Última